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Background: Potential biomarkers to aid diagnosis and therapy need to be identified for Amyotrophic Lateral
Sclerosis, a progressive motor neuronal degenerative disorder. The present study was designed to identify the
factor(s) which are differentially expressed in the cerebrospinal fluid (CSF) of patients with sporadic amyotrophic
lateral sclerosis (SALS; ALS-CSF), and could be associated with the pathogenesis of this disease.
Results: Quantitative mass spectrometry of ALS-CSF and control-CSF (from orthopaedic surgical patients undergoing
spinal anaesthesia) samples showed upregulation of 31 proteins in the ALS-CSF, amongst which a ten-fold increase in
the levels of chitotriosidase-1 (CHIT-1) was seen compared to the controls. A seventeen-fold increase in the CHIT-1
levels was detected by ELISA, while a ten-fold elevated enzyme activity was also observed. Both these results confirmed
the finding of LC-MS/MS. CHIT-1 was found to be expressed by the Iba-1 immunopositive microglia.
Conclusion: Elevated CHIT-1 levels in the ALS-CSF suggest a definitive role for the enzyme in the disease pathogenesis.
Its synthesis and release from microglia into the CSF may be an aligned event of neurodegeneration. Thus, high levels
of CHIT-1 signify enhanced microglial activity which may exacerbate the process of neurodegeneration. In view of the
multifold increase observed in ALS-CSF, it can serve as a potential CSF biomarker for the diagnosis of SALS.
Keywords: Proteomics, Cerebrospinal fluid, Sporadic amyotrophic lateral sclerosisBackground
Selective loss of cortical and spinal motor neurons is the
characteristic feature of Amyotrophic Lateral Sclerosis
(ALS), an adult onset progressive fatal neurodegenerative
disorder. Factors predisposing the most prominent form
of this multifactorial disease viz. sporadic ALS (SALS)
remain obscure due to the difficulties in developing ani-
mal models. Therefore, development of novel therapeu-
tics is also severely hampered. This is also largely
attributed to the lack of a ‘biomarker’ which can be ob-
jectively measured as an indicator of pathogenic pro-
cesses and/or pharmacologic response to therapeutic
interventions [1]. The discovery of ideal biomarkers may
offer tools for rapid diagnosis, monitoring disease* Correspondence: trraju.nimhans@gmail.com
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reproduction in any medium, provided the orprogression and provide insights into the pathophysi-
ology of the disease; thereby broadening therapeutic op-
tions. Proximity to the central nervous system (CNS)
renders Cerebrospinal Fluid (CSF) to be the ideal bio-
fluid for detection of biomarkers in CNS pathologies. It
is speculated that toxic agents which propagate the dis-
ease are synthesized in the affected areas, injure the
neighboring cells, and are released into the extracellular
space and CSF [2,3].
We have earlier shown that exposure of embryonic rat
spinal cord cultures to ALS-CSF (in-vitro) and intra-
thecal injection of the same into neonatal rats (in-vivo)
induced degenerative changes in motor neurons and
showed the involvement of astrocytes [4-11]. Intra-
cerebroventricular infusion of ALS-CSF in adult rats
perturbed the cortical motor neuronal activity and was
associated with poor motor performance [12]. Thus sev-
eral studies, including ours, support the presence ofal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eliciting its pathophysiology [3,13-15].
We undertook a study to identify the toxic factor(s) in
ALS-CSF through proteomic analysis. Quantitative mass
spectrometric analysis of ALS-CSF compared to age-
matched controls showed upregulation of 31 proteins,
amongst which Chitotriosidase-1 (CHIT-1) showed more
than 10 fold increase. The biological significance of CHIT-
1 expression is intriguing in view of the absence of its nat-
ural substrate chitin in human brain. Earlier studies have
shown an increase in CSF CHIT-1 levels in multiple scler-
osis (MS) and Alzheimer’s disease (AD) [16,17].Figure 1 Mass spectrometric analysis of ALS-CSF samples: Toxicity as
reduction in the viability of NSC-34 cells upon exposure to 10%(v/v) ALS-CS
N-CSF) and 30% compared to normal controls (***p < 0.001 vs. NC; A). ALS
control groups (***p < 0.001 vs. NC and $$$p < 0.001 vs. N-CSF; B). Gel imag
metric analysis (C). Representative MS/MS spectra of the peptides of CHIT1
Student’s t test, One way Anova followed by Tukey’s post hoc analysis.Results
Confirmation of toxicity of ALS-CSF samples
The toxicity of the ALS-CSF samples was confirmed prior
to proteomic analysis. Exposure of NSC-34 cells to the
CSF obtained from ALS patients (ALS-CSF) resulted in a
dramatic decrease in their viability when compared to the
control groups; i.e. the cells treated with CSF from normal
individuals (N-CSF) or without CSF (NC) (***p < 0.001
vs NC; ###p < 0.001 vs N-CSF; Figure 1A). It also in-
duced enhancement of LDH activity in ALS-CSF group
(***p < 0.001 vs. NC and $$$p < 0.001 vs. N-CSF;
Figure 1B).says (A & B) were performed. Histogram of MTT assay showing 40%
F compared to the cells exposed to normal-CSF (###p < 0.001 vs.
-CSF caused significant increase in LDH activity when compared to
e representing depletion of abundant proteins prior to mass spectro-
, Osteopontin, CHI3L1 and CHI3L2 (D). Tests of significance was
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Ten CSF samples each from controls and ALS were
pooled, depleted of abundant proteins and electropho-
resed on SDS-PAGE (Figure 1C). Total protein from
control and ALS-CSF were subjected to tryptic diges-
tion, followed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) after labeling with isobaric
tags for relative and absolute quantitation (iTRAQ). LC-
MS/MS analysis identified 819 proteins using SEQUEST
and Mascot (Additional file 1: Table S1). Approximately
31 proteins showed more than 1.5-fold increase, suggest-
ing an up- regulation (Additional file 2: Table S2) and
about 17 proteins were down-regulated (decrease of 0.5
fold or more) in ALS-CSF samples compared to the nor-
mal controls (Additional file 3: Table S3). Four of the
prominently up-regulated proteins were CHIT-1 (10 fold),
osteopontin isoform-b (3 fold), chitinase-3-like protein 2
(CHI3L2; 2 fold) and chitinase-3-like protein 1 (CHI3L1;
1.7 fold). Thus CHIT-1 showed the most dramatic in-
crease (Table 1, Figure 1D).Validation of LC-MS/MS data by ELISA
Observations obtained by LC-MS/MS were confirmed
by ELISA. The basal values of CHIT-1 in the control
CSF ranged as wide as 80 – 1250 pg/ml, with a mean of
982 ± 245 (n = 11). In the ALS-CSF, the level of CHIT-1
ranged between 5000 – 54,000 pg/ml, with a mean of
17570 ± 4883 pg/ml (n = 16). The mean increase in the
ALS-CSF was approximately 17 fold (**p < 0.01 vs N-
CSF; Figure 2A). Amongst the tested CSF samples of
ALS patients, 27% showed a 4-fold increase, whereas
73% showed an increase of 10-fold or more.
Similar to the LC-MS/MS data, CHI3L2 levels showed
approximately 2-fold increase (**p < 0.01 v/s N-CSF; no.
of samples: N-CSF =13, ALS-CSF = 16) while osteopon-
tin levels showed 1.9-fold increase in ALS-CSF com-
pared to the control CSF (*p < 0.05 v/s N-CSF; no. of
samples: N-CSF =13, ALS-CSF = 16) (Figure 2B & C).
Although the CHI3L1 level was also increased, the
change was not statistically significant (Figure 2D).Table 1 List of proteins upregulated in ALS-CSF
S. No Gene
symbol
Protein name Relative expression
(ALS-CSF/N-CSF)
fold change
1 CHIT1 chitotriosidase-1 precursor
[Homo sapiens]
10
2 SPP1 osteopontin isoform b
precursor [Homo sapiens]
3
3 CHI3L2 chitinase-3-like protein 2
isoform c [Homo sapiens]
2
4 CHI3L1 chitinase-3-like protein 1
precursor [Homo sapiens]
1.7Validation of LC-MS/MS data by enzyme assay
The CHIT-1 in the CSF samples catalyzed the conversion
of 4-methylumbelliferyl-β - d N, N’, N” –triacetylchito-
triose to 4-methylumbelliferone confirming that the en-
zyme was biologically active. The CHIT-1 activity in the
control CSF ranged between 0.0169 – 0.1856 μmol/min/μl
(Mean: 0.02459 ± 0.01499; n = 13) whereas in the ALS-
CSF it was 0.0809 – 4.1658 μmol/min/μl (Mean:
0.9932 ± 0.3023; n = 16). Thus the patient CSF samples
revealed approximately a 10-fold higher enzymatic ac-
tivity (**p < 0.001 vs N-CSF; Figure 2E).
CHIT-1 expression in microglia
The Iba-1 immunoreactive pure microglial cultures
when exposed to ALS-CSF, showed an elevated expres-
sion of CHIT-1 compared to control cultures (Figure 3).
Discussion
This is the first report demonstrating an increase in the
levels of four proteins namely, CHIT-1, osteopontin,
CHI3L2 and CHI3L1 in the CSF of ALS patients using
the novel and precise quantitative proteomics and
ELISA. Similar patterns were observed with both LC-
MS/MS of pooled CSF and ELISA of individual CSF.
Amongst these the increase in CHIT-1 levels being most
dramatic; further experiments were focused on this pro-
tein. A profound increase in CHIT-1 enzymatic activity
was confirmed in ALS-CSF compared to normal CSF.
Accordingly, it is likely to be an important biomarker
which may help track the progression of the disease.
CHIT-1 could have a role in causing toxicity propagated
by the CSF, since the ALS-CSF samples used in the
present study also contained neurodegenerative attri-
butes as confirmed by MTT and LDH assays.
CHIT-1 is classically associated with lysosomal storage
diseases like Gaucher’s disease, due to its increased
levels in the patients’ CSF [18]. Chitin is the natural sub-
strate of CHIT-1, but is thought to be absent in the hu-
man brain. However, it is intriguing to know that even
in the absence of the substrate the enzyme is synthesized
by microglia or infiltrating macrophages [19].
It is uncertain whether CHIT-1 activity directly affects
the CNS or symbolizes an archaic macrophage response
against chitin-containing pathogens [19,20]. Chitin is an
insoluble N-acetylglucosamine polymer found in inverte-
brates and human parasites [21,22]. In its absence, alter-
native substances e.g. chitin-like glucosamine polymers
may be its likely substrate. In post mortem brains of AD
patients, presence of glucosamine polymers in amyloid
plaques hints at its role in disease pathogenesis [16]. It is
also suggested that chitin-like polysaccharides provide
scaffolding for β-amyloid deposition thus facilitating the
disease process [23]. Higher CHIT-1 expression in post
mortem brains of AD patients [24] underlines the co-
Figure 2 Validation of upregulated proteins by ELISA and CHIT-1 activity assay. Chitotriosidase was found to be 17 fold upregulated
(**p < 0.01 vs. N-CSF; A) and chitinase 3- like-2 (CHI3L2) showed ~2 fold increase (**p < 0.01 vs. N-CSF; B) in ALS-CSF. Osteopontin showed ~ 1.9 fold
upregulation (*p < 0.05 vs. N-CSF; C) whereas, upregulation in Chitinase 3- like-1 (CHI3L1) levels was statistically non- significant (D). Histogram showing
CHIT-1 enzymatic activity in CSF samples. The activity was found to be 10 fold higher in ALS-CSF (**p < 0.001 vs. N-CSF; E).
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deposition of β-amyloid [25].
It is reported that higher CSF CHIT-1 levels in MS pa-
tients correlate well with the disease progression [26]. In
the MS patients, the increase in CSF CHIT-1 levels was
approximately two-fold, however we observed approxi-
mately 10-fold increase in CHIT-1 levels in the patient
CSF. Although it is not justified to compare the differ-
ences in the patients’ CSF as their study was on MS
whereas we studied ALS patients, it is also likely that the
differences in fold levels of CSF CHIT-1 are indeed high
in ALS compared to MS.
Contrary to AD, deposits of chitin-like substances were
absent in MS. Although microglia and infiltrating macro-
phages driven innate immune response was a classical
molecular feature of MS, the products of the latter pro-
cesses viz. cytokines, ROS etc. were not substantialenough to establish any clinico-pathological co-relation
[17]. However, Correale and Fiol reported that the en-
hanced level of CSF chitinases driven by IL-13 could con-
tribute to neuroinflammation by increasing immune cell
migration across the blood–brain barrier in the CNS [26].
The enhanced expression of CHIT-1, by microglia,
possibly indicates a neuroinflammatory response. CHIT-
1 is an index of the severity of inflammation alongside
the release of pro-inflammatory cytokines like IL-16 and
IL-18 [27]. In stroke, CHIT-1, TNF-α and other pro-
inflammatory cytokines are accepted as markers of micro-
glial activation, occurring independent of pre-existing
inflammatory or infectious conditions in patients [28]. Ac-
cording to an alternative hypothesis, CHIT-1 is speculated
to be neuroprotective, in view of the reduction in glucosa-
mine aggregates following intrathecal CHIT-1 administra-
tion in MS [17]. Even in AD, enhanced levels of CHIT-1
Figure 3 Expression of CHIT-1 in microglial cultures. Immunoflourescence photomicrographs of pure microglial cultures labeled with CHIT-1
(green; A, D) and Iba-1, a marker for microglia (red; B, E). Note the increased expression of CHIT-1 in the cultures exposed to ALS-CSF (D) as
compared to the normal control (A). The merged images (C and F) depict the co-labeling of CHIT-1 with Iba-1 in normal control (A) and ALS
group (D) respectively.
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activated microglia-macrophage complex to clear the
pathogenic chitin-like substances [16,25]. Its role in ALS
is yet to be deciphered.
Conclusion
Although studies report higher CSF CHIT-1 levels in
several neurological diseases including MS, AD and
stroke, no study till date documents its elevated levels in
ALS, where maximum increase was observed compared
to other neurodegenerative diseases. The mechanisms of
CHIT-1 induction in each of the neurological disorders
appear to be unique to the disease. Collectively, ourTable 2 Details of ALS-CSF
CSF for iTRAQ study
Gender Male – 7 (70%)
Age at presentation (Mean ± SD) 47.40 ± 4.95 (38 – 54) Years
Age at onset 46 ± 5.05 (37 – 53) Years
Duration of illness (Mean ± SD) 15.9 ± 13.4 (4.0 – 48) months
Onset Patter: Bulbar 1 (10%)
Limb onset 9 (90%)
Upper Limbs 9
Lower Limbs 6
Speech affected 80% (Mild – 30%, Moderate – 30%, Severe
Dysphagia 80% (Mild – 30%, Moderate – 30%, Severe
Spasticity 9 cases, with evidence of pyramidal signs
the form of spasticity and exaggerated
Deep Tendon Reflexesfindings of steep increase in CSF CHIT-1 levels in SALS
along with stable bioactivity render it a biomarker status
and may find applications in developing therapeutic
strategies for sporadic ALS.
Materials and methods
CSF sample collection
ALS-CSF samples from patients with a mean age of
47.38 ± 5.38 years and disease duration of 0.5 to 2.5 years
were obtained. N-CSF samples were drawn from age-
matched patients undergoing spinal anaesthesia for
orthopaedic surgery but without any clinical history
of neurological deficits (mean age 45.7 ± 7.04 years)CSF for validation
Female – 3 (30%) Male – 10 (62.5%) Female – 6 (37.5%)
47.38 ± 5.38 (38 – 54) Years
46.28 ± 5.36 (37 – 53) Years





– 20%) 87.5% (Mild – 31.25%, Moderate – 31.25%, Severe – 25%)
– 20%) 93.75% (Mild – 31.25%, Moderate – 18.75%, Severe −12.5%)
in 11 cases, with evidence of pyramidal signs in the form of
spasticity and exaggerated Deep Tendon Reflexes
Table 3 Details of N-CSF
CSF for iTRAQ study CSF for validation









(Mean ± SD in years)
47.3 ± 6.99 (39 – 60) 45.7 ± 7.04 (39 – 60)
Patients undergoing orthopaedic surgery
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in liquid nitrogen and stored at –80°C. Informed con-
sent for CSF sample collection was obtained as per
the institutional human ethics committee guidelines.
Cell culture
We followed a modified protocol to establish pure
microglial cultures from P0 Wistar rat pups [29]. Briefly,
the spinal cords were dissected, freed of meninges and
mechanically triturated in Dulbecco’s Modified Eagle
Medium (DMEM) and propagated in DMEM with 10%
FBS (GIBCO-BRL). The mixed glial cultures wereFigure 4 A schematic representation of the procedural steps for mass
spectrometry after sequential treatment procedures like, depletion of abun
molecules were validated using ELISA.allowed to attain 100% confluence. On 10th day in-vitro
(DIV), the cultures were placed on incubated orbital
shaker at 200 rpm for 3–4 hrs. The supernatant contain-
ing microglia was centrifuged at 1500 rpm for 5 min,
and the pelleted cells were seeded onto poly-l-lysine
coated coverslips at the density of 4.4×104 cells/ml. The
cultures were maintained in DMEM with 10% FBS
(GIBCO-BRL). The cells were then exposed to ALS-
CSF or allowed to propagate under normal conditions.
NSC-34 cell line (Cedarlane Corporation, Canada)
routinely maintained in DMEM with 10% FBS [30] was
used to analyze the neurotoxic effects of individual ALS-
CSF samples.
Cell viability/death assays
NSC-34 cells seeded into 96 well plates (500 cells/well)
were exposed to 10% v/v N-CSF or ALS-CSF on 5th
DIV for 48 hrs, and then subjected to MTT assay (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) and LDH assay [30].spectrometric analysis. Pooled CSF samples were subjected to mass
dant proteins, tryptic digestion, iTRAQ labelling and SCX. Selected
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Depletion of abundant proteins in CSF
CSF samples from controls (n = 10) and ALS patients
(n = 10) were pooled individually and used for iTRAQ
based quantitative proteomic comparison by mass spec-
trometry (Figure 4). Samples were centrifuged at
10,000 rpm for 10 min to remove cell debris. Agilent’s
multiple affinity removal system (MARS-14), generally
used for depletion of albumin, IgG, transferrin, heptoglo-
bin, IgM, IgA, fibrinogen, alpha antitrypsin, apolipoprotein
A1, alpha1 acid glycoprotein, alpha2 macroglobin, trans-
thyretin, complement C3 and apolipoproteins was used to
deplete the abundant proteins from CSF samples [31].
Briefly, MARS-14 cartridge was conditioned using 4 ml of
Buffer-A (50 g, 1 min). CSF (300 μl) was loaded on to the
cartridge and spun at 50 g for 1 min. Flow through was
collected and reloaded on to the cartridge, incubated for
5 minutes at room temperature (RT) and spun at 50 g for
1 min. Flow through was re-collected and the bound pro-
teins were eluted using 2.4 ml of Buffer-B. The cartridge
was conditioned again using buffer-A and the process was
repeated until the abundant proteins were depleted. The
fractions were concentrated using Millipore filter (3 kDa).
This step also ensures removal of salts contributed by the
buffers used during depletion steps.
Protein estimation was carried out using Lowry’s
method. 200 μg protein each from controls and ALS was
used for proteomic comparison. Sample normalization
was based on total protein amount which was further
verified by SDS-PAGE.
iTRAQ labelling and strong cation exchange
chromatography
Individual depleted extract (125 μg) was treated with
2% SDS and reducing agent (2 μl; 60°C for 1 hr) and
alkylated with 1 μl of cysteine blocking agent for
10 min at RT. Proteins were digested overnight at 37°C
using sequencing grade trypsin at 1:20 (w/w) ratio.
Thereafter, peptides from N-CSF and ALS-CSF were la-
beled using iTRAQ reagents yielding reporter ions of
m/z114 and 115 respectively, for 2 hrs at RT. The reac-
tion was quenched by adding 100 μl of water and the
peptides from both N-CSF and ALS-CSF were pooled
and fractionated using strong cation exchange (SCX)
chromatography. The labeled samples were distributed
into 19 fractions using SCX. The fractions were
desalted using C18 zip tips, dried and reconstituted in
10 μl of 0.1% trifluoroacetic acid before mass spectrom-
etry analysis [32].
LC-MS/MS analysis
LC-MS/MS analysis of iTRAQ-labeled peptides was
carried out on an LTQ-Orbitrap Velos mass spectrom-
eter (Thermo Electron, Bremen, Germany) interfacedwith Agilent’s 1200 series nanoflow liquid chromatog-
raphy system (Agilent Technologies, Santa Clara, CA).
Each sample was loaded on to the enrichment column
(75 μm × 2 cm, 5 μm, 120 Å, Magic C18 AQ
MichromBioresources) at a flow rate of 3 μl/min and
then resolved on an analytical column (75 μm× 10 cm,
5 μm, 120 Å, Magic C18 AQ MichromBioresources) at a
flow rate of 300 nl/min using a linear gradient of 10% -
40% solvent B (90% acetonitrile in 0.1% TFA) over a
period of 70 min. The total run time per sample was
115 min. The resolved peptides from analytical column
were delivered to LTQ Orbitrap Velos mass spectrometer
through an emitter tip (8 μm, New Objective, Woburn,
MA). LC-MS/MS data was acquired in a data dependent
manner in FT- FT mode. MS spectra were acquired with a
mass range of m/z 350 to 1800. Twenty most abundant
precursor ions were selected for fragmentation from
each MS scan. Data was acquired at MS resolution of
60,000 (m/z 400) and MS/MS resolution of 15,000. Pre-
cursor ion fragmentation was carried out using higher en-
ergy collision (HCD) mode with normalized collision
energy of 41%. Monoisotopic precursor selection was en-
abled and the precursor ions that were selected for frag-
mentation were dynamically excluded for 30 sec [32].
Data analysis
The MS data was analyzed using the Proteome Discoverer
software (Thermo Scientific, version 1.2). The data was
searched against human protein database (NCBI RefSeq
45) along with known contaminants using SEQUEST and
MASCOT search algorithms. The parameters used for
data analysis included trypsin as a protease (allowed
one missed cleavage), iTRAQ labeling at N-terminus
and lysine residues, and cysteine modification by me-
thyl methanethiosulfonate (MMTS) as fixed modifica-
tions and oxidation of methionine as a variable
modification. The precursor ion mass error tolerance
was set to 20 ppm and product ion mass error toler-
ance was set to 0.1 Da. The peptide data was extracted
using 1% FDR as a threshold. Relative abundance of
proteins between N-CSF and ALS-CSF was determined
by Proteome Discoverer based on difference in the peak
intensity of reporter ions in the MS/MS spectra of each
peptide that was ultimately used for quantifying the
corresponding protein.
Enzyme linked immunosorbent assays (ELISA)
N-CSF (n = 13) and ALS-CSF samples (n = 16) were
subjected to ELISA based analysis using commercially
available kits for CHIT-1 (MBL, Italy; CSF dilution fac-
tor (cdf ): N-CSF: undiluted; ALS-CSF 1:20), CHI3L1
(Quidel, USA), CHI3L2 (USCN, China; cdf 1:1) and
Osteopontin (R&D Systems; cdf 1:50). The protocol
was followed as per the manufacturer’s instructions.
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4-methylumbelliferyl-β - d N, N’, N” –triacetylchitotriose
(Sigma-Aldrich USA) was used as a substrate to assay
the enzyme activity. CSF (2.5 g protein) was added to
150 μl of 22 μmol solution prepared in 0.5 M citrate-
phosphate buffer (pH 5.2). Following incubation for
15 min at 37°C, the reaction was stopped using 100 μl of
0.5 mol Na2CO3 -NaHCO3 buffer (pH 10.7). The fluor-
escence was recorded at 365 nm excitation/450 nm
emissions (Tecan 2500 flouorimeter, USA) and mea-
sured as micromoles of substrate hydrolysed/min/l.Immunocytochemistry
Fixed primary microglial cultures were stained with
rabbit polyclonal anti-CHIT-1 antibody (1:1000, Santa-
cruz, USA) for 24 hr after blocking with 3% bovine
serum albumin (BSA) (Sigma–Aldrich, USA) and de-
tected using FITC-conjugated anti-rabbit secondary anti-
body (1:200, Sigma–Aldrich, USA). The cultures were
further incubated with a goat polyclonal anti Iba-1 anti-
body (1:400, Abcam, UK) for 24 hr and detected with
CY3-conjugated anti-goat antibody (1:200, Sigma–Aldrich,
USA). The staining was viewed using confocal microscopy
(488 nm and 514 nm for FITC and Cy3, respectively;
Leica-TCS-SL, Germany). The emission frequencies were
segregated to avoid non-specific overlap of labelling [11].Statistical analysis
The data was statistically assessed for significance by
either Student’s t test or one way ANOVA as applicable,
followed by Tukey’s post hoc tests.Additional files
Additional file 1: Table S1. List of proteins identified in ALS-CSF.
Description of Data: A list of the peptides and their fold changes of the
819 proteins identified in ALS-CSF using SEQUEST and Mascot.
Additional file 2: Table S2. Up-regulated proteins in ALS-CSF.
Description of data: Table showing 31 up-regulated proteins with more
than 1.5-fold increase in ALS-CSF compared to normal CSF.
Additional file 3: Table S3. Proteins down-regulated in ALS-CSF.
Description of Data: List of 17 down-regulated proteins which showed a
decrease of 0.5 fold or more, in ALS-CSF samples.Abbreviations
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